Effectiveness of favipiravir in comparison with Tenofovir Alafenamid in patients with COVID-19
Phase 2
Recruiting
- Conditions
- COVID-19.COVID-19U07.1
- Registration Number
- IRCT20150808023559N23
- Lead Sponsor
- Ardabil University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Diagnosis of COVID-19 based on chest CT scan or positive PCR test for COVID-19
Requiring hospitalization
Patient's age between 16 and 100 years
Signing informed consent form
Exclusion Criteria
Receiving other antiviral medicationsrenal failure
Pregnancy
HIV
Lactation
Renal failure
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Hospital mortality. Timepoint: Up to two weeks after the intervention on a daily basis. Method of measurement: Patient medical records.
- Secondary Outcome Measures
Name Time Method Duration of hospitalization. Timepoint: From the time of hospitalization to the patient's discharge from the hospital. Method of measurement: Patient medical records.